(LTRN) Lantern Pharma Inc. Business Model Canvas Research

Academic and translational research collaborators help Lantern Pharma Inc. validate targets, biomarkers, and preclinical signals across its oncology programs. These partnerships also support mechanism-of-action and translational studies, which strengthens scientific credibility and widens access to external expertise.

• Validate targets and biomarkers
• Support mechanism-of-action work
• Improve external knowledge access

Lantern Pharma uses regulatory and clinical advisors to shape IND plans, trial design, and oncology filing strategy across its 3 lead programs. This helps align development packages with FDA expectations and cuts rework risk for a clinical-stage company moving multiple assets at once.

• IND strategy support
• Trial design and endpoints
• FDA-ready oncology packages

Lantern Pharma Inc. keeps LP-184 in preclinical optimization as a DNA-damaging alkylating agent for biomarker-defined tumors, while its ADC program expands the pipeline into targeted cancer delivery. Both tracks depend on preclinical testing, modeling, and candidate refinement to improve tumor selectivity and kill signal before clinical entry.

• LP-184: biomarker-linked alkylator
• ADC: targeted delivery extension
• Needs testing, modeling, refinement

Lantern Pharma Inc. continuously folds molecular, genomic, and clinical data into RADR, so each new dataset sharpens signal detection, response prediction, and patient subgroup selection. This repeatable workflow ties research to development and supports faster go/no-go calls across the pipeline.

• Integrates real-world and trial data
• Improves biomarker-driven selection
• Links discovery to development

Lantern Pharma Inc.’s scientific and clinical expertise is a core key resource because its precision-oncology model depends on oncology biology, computational science, and clinical development talent to design assays, read data, and run trials. This human capital is what turns AI-led drug discovery into usable oncology programs.

• Supports assay design
• Drives data interpretation
• Enables trial execution
• Critical for precision oncology

Lantern Pharma Inc.'s Dallas, Texas headquarters is the core of its operating setup, housing management, development planning, and administrative work. It also supports coordination across research, clinical, and external partners, which matters for a lean biotech operating model.

• Dallas HQ: management and admin hub
• Supports research and clinical coordination
• Centralizes partner communications

Lantern Pharma Inc. targets defined cancer settings with biomarker-linked programs, not broad oncology use. That sharp focus can shorten trial design and improve message fit; the platform centers on 3 lead programs, including LP-184, LP-284, and LP-300.

• 3 lead programs, each for a clear cancer niche
• Biomarker-driven positioning
• More focused clinical development

Lantern Pharma Inc.'s RADR platform is built to cut time and cost in candidate selection and trial design by ranking assets on biological plausibility before cash-heavy wet-lab work starts. That speed matters: the company had $12.5 million in cash and equivalents at Q1 2024, so tighter development efficiency is a real investor and partner value driver.

• Faster candidate prioritization
• Lower trial design waste
• Higher hit rate on assets

Lantern Pharma Inc. keeps a formal, evidence-based line with regulators, because every oncology step from IND to later-stage trials depends on clear data, clean filings, and fast feedback. This relationship shapes trial design, endpoints, and submission timing, so it is central to moving assets through clinical stages.

• Formal, evidence-led contact
• Guides trial and filing choices
• Critical for oncology progress

Regulatory dialogue is not optional here; it is part of the development path and can affect speed, cost, and approval odds.

Lantern Pharma Inc. runs a partnership-based support model, relying on external collaborators instead of a fully integrated operating setup, so customer work depends on structured handoffs and milestone-based coordination. That keeps Lantern Pharma asset- and platform-focused, with partner execution helping scale without building a large in-house commercial stack.

• External partners handle key operational steps.
• Milestones keep work tightly coordinated.
• Model preserves Lantern Pharma focus.

Lantern Pharma Inc. uses its corporate website and digital channels to publish pipeline, platform, and company updates for investors, clinicians, and partners. For a clinical-stage company with no marketed products, this low-cost layer is central to reach and trust.

• Share pipeline and RADR updates online
• Support investor and partner visibility
• Keep communication costs low

Lantern Pharma Inc. uses direct business development outreach to pharma, biotech, and research partners to open licensing and collaboration talks around its AI-driven drug assets. This channel matters because partnering can turn 1 platform into multiple commercial paths, and Lantern Pharma reported $0 product revenue in 2025, so external deals remain key to monetization.

• Targets licensing and co-development
• Builds future partnering pipeline
• Converts science into commercial value

Public shareholders and capital markets fund Lantern Pharma Inc.’s clinical work, so they watch pipeline readouts, platform edge, and milestone risk very closely. In FY2025, the key signal for this segment is continued capital support for a pre-revenue, development-stage biotech, where valuation still depends on data, not sales.

• Funds trials and R&D
• Tracks pipeline milestones
• Prices platform differentiation

Academic groups and translational researchers are key users of Lantern Pharma Inc.’s scientific output and biomarker work, helping test mechanism claims and patient-selection hypotheses in real datasets. Their feedback strengthens the evidence base for LP-300, LP-184, and other platform programs, while also supporting reproducible, publishable validation work.

• Validate targets and biomarkers
• Refine patient selection logic
• Boost evidence for platform programs

RADR’s data storage, analytics, and cloud compute are recurring cost drivers because machine learning and big-data processing need constant training, retrieval, and model updates. For Lantern Pharma Inc., these costs are core to keeping the platform usable and improving target discovery, so they scale with data volume and model complexity.

• Recurring cloud storage and compute spend
• Ongoing ML model training costs
• Big-data processing and analytics load
• Platform upkeep and performance gains

Lantern Pharma’s regulatory, legal, and public-company costs are recurring overhead tied to SEC reporting, audit, governance, and compliance. IP defense and regulatory strategy also add steady spend, so this cost line stays fixed even when R&D changes.

• SEC reporting and audit costs recur
• IP protection adds legal spend
• Compliance overhead is structural

Future milestone-based deal revenue at Lantern Pharma Inc. would come from partnership or licensing deals when clinical or regulatory steps are hit, so cash arrives only as programs advance. In FY2025, Lantern Pharma reported no material collaboration revenue, which shows how dependent this stream is on later-stage progress.

• Triggered by trial and FDA milestones

• Linked to partner or license contracts

• Revenue can be lumpy, not steady

RADR can become a platform revenue engine through technology access fees, paid analytics, and partnered discovery programs. Lantern Pharma is still pre-commercial, so even one recurring license or alliance tied to its AI and genomics stack could matter more than near-term product sales.

• Technology access fees

• Analytical services

• Partnered discovery deals